Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis

Table 3

Hazard ratio, 95% confidence intervals, and value for EDSS and T25FW worsening comparing teriflunomide and glatiramer acetate-treated patients.

	Unadjusted		Adjusted^a
	HR (95% CI)	value	HR (95% CI)	value
EDSS sustained progression	1.17 (0.46, 2.97)		1.17 (0.45, 3.08)
T25FW sustained worsening	0.61 (0.25, 1.53)		0.56 (0.2, 1.53)
T25FW sustained worsening^b	0.46 (0.12, 1.77)		0.31 (0.07, 1.38)

EDSS: expanded disability status scale; T25FW: timed 25-foot walk; HR: hazard ratios; CI: confidence intervals. ^aAdjusted analysis for baseline age, sex, and EDSS. ^bSensitivity analysis excluding patients with a change in dalfampridine or assistive device use.